Stereotactic Ablative Radiation for Pancreatic Cancer on a 1.5 Telsa Magnetic Resonance-linac System

Overview

Journal Phys Imaging Radiat Oncol

Specialty Oncology

Date 2022 Nov 17

PMID 36386447

Authors

Kathryn R Tringale

Neelam Tyagi

Marsha Reyngold

Paul B Romesser

Abraham Wu

Eileen M OReilly

Anna M Varghese

Paola Godoy Scripes

Danny N Khalil

Wungki Park

Kenneth Yu

Christopher H Crane

Affiliations

Soon will be listed here.

Abstract

Purpose: Ablative radiation therapy (A-RT) appears to improve outcomes in locally advanced pancreatic cancer (LAPC) yet requires solutions for respiratory and digestive motion. We report outcomes of A-RT for pancreatic cancer using 1.5 T MR-adaptive treatment delivery.

Methods: Between March 2020 and July 2021, we treated 30 patients with pancreatic cancer with 50 Gy in 5 fractions (biologically effective dose [BED10] = 100 Gy10) using a novel compression belt workflow and remote planning on the Unity 1.5 T MR linac system. Cumulative incidence of progression was computed from A-RT initiation with death as a competing risk. Overall (OS) and progression-free survival (PFS) were calculated using Kaplan Meier methods.

Results: Of 30 patients, most (73 %) were locally advanced, 4 (13 %) were metastatic, 2 (7 %) were medically inoperable, and 2 (7 %) were locally recurrent. Most (73 %) received FOLFIRINOX prior to A-RT. Median follow-up times from diagnosis and A-RT were 17.6 (IQR 15.8-23.1) and 11.5 months (IQR 9.7-16.1), respectively. Cumulative incidences at 1-year of local and distant progression were 19.3 % (95 %CI 6.7-36.8 %) and 47.4 % (95 %CI 26.7-65.6 %), respectively. Median OS from diagnosis and A-RT were not reached. One-year OS from diagnosis and A-RT were 96.4 % (95 %CI 77.2-99.5 %) and 80.0 % (95 %CI 57.3-91.4 %), respectively. Median and 1-year PFS were 10.1 months (95 %CI 4.4-14.4) and 39.7 % (95 %CI 20.3-58.5 %), respectively. No grade 3 + toxicities were observed.

Conclusions: A-RT using the 1.5 T Unity MR Linac resulted in promising LC and OS with no severe toxicity in patients with LAPC despite radiosensitive organs adjacent to the target volumes. Longer follow-up is needed to assess long-term outcomes.

Citing Articles

Non-medicinal oral contrast in upper abdominal MRI for MR-guided radiotherapy: A scoping review.

Beasley M, Henry A, Bestall J, Cosgrove V, Murray L, Burnett C Radiography (Lond). 2025; 31(2):102868.

PMID: 39863498 PMC: 11904122. DOI: 10.1016/j.radi.2025.01.003.

Feasibility of quantitative relaxometry for prostate target localization and response assessment in magnetic resonance-guided online adaptive stereotactic body radiotherapy.

Subashi E, LoCastro E, Burleson S, Apte A, Zelefsky M, Tyagi N Phys Imaging Radiat Oncol. 2024; 32():100678.

PMID: 39717186 PMC: 11665667. DOI: 10.1016/j.phro.2024.100678.

Stereotactic body radiation therapy for the primary tumor and oligometastases versus the primary tumor alone in patients with metastatic pancreatic cancer.

Jiang L, Ye Y, Feng Z, Liu W, Cao Y, Zhao X Radiat Oncol. 2024; 19(1):111.

PMID: 39160547 PMC: 11334573. DOI: 10.1186/s13014-024-02493-8.

Total Neoadjuvant Therapy in Localized Pancreatic Cancer: Is More Better?.

Saude-Conde R, El Ghali B, Navez J, Bouchart C, Van Laethem J Cancers (Basel). 2024; 16(13).

PMID: 39001485 PMC: 11240662. DOI: 10.3390/cancers16132423.

Treatment planning for MR-guided SBRT of pancreatic tumors on a 1.5 T MR-Linac: A global consensus protocol.

Grimbergen G, Eijkelenkamp H, Snoeren L, Bahij R, Bernchou U, van der Bijl E Clin Transl Radiat Oncol. 2024; 47:100797.

PMID: 38831754 PMC: 11145226. DOI: 10.1016/j.ctro.2024.100797.

References

Iacobuzio-Donahue C, Fu B, Yachida S, Luo M, Abe H, Henderson C . DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009; 27(11):1806-13. PMC: 2668706. DOI: 10.1200/JCO.2008.17.7188. View

Cox J, Stetz J, Pajak T . Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31(5):1341-6. DOI: 10.1016/0360-3016(95)00060-C. View

Rahib L, Wehner M, Matrisian L, Nead K . Estimated Projection of US Cancer Incidence and Death to 2040. JAMA Netw Open. 2021; 4(4):e214708. PMC: 8027914. DOI: 10.1001/jamanetworkopen.2021.4708. View

Krishnan S, Chadha A, Suh Y, Chen H, Rao A, Das P . Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. Int J Radiat Oncol Biol Phys. 2016; 94(4):755-65. PMC: 4792191. DOI: 10.1016/j.ijrobp.2015.12.003. View

Placidi L, Romano A, Chiloiro G, Cusumano D, Boldrini L, Cellini F . On-line adaptive MR guided radiotherapy for locally advanced pancreatic cancer: Clinical and dosimetric considerations. Tech Innov Patient Support Radiat Oncol. 2020; 15:15-21. PMC: 7334416. DOI: 10.1016/j.tipsro.2020.06.001. View

Hassanzadeh C, Rudra S, Bommireddy A, Hawkins W, Wang-Gillam A, Fields R . Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation. Adv Radiat Oncol. 2021; 6(1):100506. PMC: 7897757. DOI: 10.1016/j.adro.2020.06.010. View

Schellenberg D, Goodman K, Lee F, Chang S, Kuo T, Ford J . Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2008; 72(3):678-86. DOI: 10.1016/j.ijrobp.2008.01.051. View

Suker M, Beumer B, Sadot E, Marthey L, Faris J, Mellon E . FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016; 17(6):801-810. PMC: 5527756. DOI: 10.1016/S1470-2045(16)00172-8. View

Conroy T, Hammel P, Hebbar M, Abdelghani M, Wei A, Raoul J . FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018; 379(25):2395-2406. DOI: 10.1056/NEJMoa1809775. View

10.

Paulson E, Ahunbay E, Chen X, Mickevicius N, Chen G, Schultz C . 4D-MRI driven MR-guided online adaptive radiotherapy for abdominal stereotactic body radiation therapy on a high field MR-Linac: Implementation and initial clinical experience. Clin Transl Radiat Oncol. 2020; 23:72-79. PMC: 7256110. DOI: 10.1016/j.ctro.2020.05.002. View

11.

Bohoudi O, Bruynzeel A, Senan S, Cuijpers J, Slotman B, Lagerwaard F . Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer. Radiother Oncol. 2017; 125(3):439-444. DOI: 10.1016/j.radonc.2017.07.028. View

12.

Strobel O, Neoptolemos J, Jager D, Buchler M . Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol. 2018; 16(1):11-26. DOI: 10.1038/s41571-018-0112-1. View

13.

Hoyer M, Roed H, Sengelov L, Traberg A, Ohlhuis L, Pedersen J . Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol. 2005; 76(1):48-53. DOI: 10.1016/j.radonc.2004.12.022. View

14.

Chuong M, Bryant J, Mittauer K, Hall M, Kotecha R, Alvarez D . Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided Radiation Therapy With On-Table Adaptive Replanning and Elective Nodal Irradiation for Inoperable Pancreas Cancer. Pract Radiat Oncol. 2020; 11(2):134-147. DOI: 10.1016/j.prro.2020.09.005. View

15.

Blazer M, Wu C, Goldberg R, Phillips G, Schmidt C, Muscarella P . Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 2014; 22(4):1153-9. PMC: 4373613. DOI: 10.1245/s10434-014-4225-1. View

16.

Bohoudi O, Bruynzeel A, Meijerink M, Senan S, Slotman B, Palacios M . Identification of patients with locally advanced pancreatic cancer benefitting from plan adaptation in MR-guided radiation therapy. Radiother Oncol. 2019; 132:16-22. DOI: 10.1016/j.radonc.2018.11.019. View

17.

Henke L, Kashani R, Robinson C, Curcuru A, DeWees T, Bradley J . Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiother Oncol. 2017; 126(3):519-526. DOI: 10.1016/j.radonc.2017.11.032. View

18.

Crane C, Varadhachary G, Yordy J, Staerkel G, Javle M, Safran H . Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol. 2011; 29(22):3037-43. PMC: 3157965. DOI: 10.1200/JCO.2010.33.8038. View

19.

Rudra S, Jiang N, Rosenberg S, Olsen J, Roach M, Wan L . Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. Cancer Med. 2019; 8(5):2123-2132. PMC: 6536981. DOI: 10.1002/cam4.2100. View

20.

Teriaca M, Loi M, Suker M, Eskens F, van Eijck C, Nuyttens J . A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome. Radiother Oncol. 2020; 155:232-236. DOI: 10.1016/j.radonc.2020.11.006. View